Hebrew University of Jerusalem launched 15 spinouts last year covering areas ranging from healthcare to solar energy.

Yissum, the technology transfer arm of Hebrew University of Jerusalem, launched a total of 15 spinouts last year.

The companies are:

  • RNAWay, which has developed a platform for delivering siRNA to plants;
  • Immunyx Pharma, which is working on technology for neutrophil specific targeting a mode of immunotherapy;
  • Lipovac, which has set its sights on a liposome-based vaccine to treat conditions including covid;
  • ExoNavis Therapeutics, which is focusing on exosome-based drug delivery;
  • NexoCarp, which is pickering solid dispersion and particles for the delivery of agents;
  • PSYRX, a tissue culture protocols developer targeting central nervous system diseases;
  • MyComed Super Foods, which plans to use medicinal herbs and spirulina algae to prevent osteoporosis;
  • Cavos, which is exploiting artificial intelligence and machine learning to create diagnostic, prognostic and treatment options for a range of diseases;
  • Noga3D, which will market 3D-printing materials based on epoxies;
  • I-Red Pharma, which will commercialise a treatment for conditions with new small and multi-property molecules;
  • Solra, which plans to sellfully screen-printable…

    Subscribe to go deeper

    GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



    Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).